Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer.

Indira Chandran, Vineesh LU ; Eppenberger-Castori, Serenella ; Venkatesh, Thejaswini ; Vine, Kara Lea and Ranson, Marie (2015) In Oncoscience 2(3). p.207-224
Abstract
Human epidermal growth factor receptor type 2 (HER2)-positive breast carcinoma is highly aggressive and mostly metastatic in nature though curable/manageable in part by molecular targeted therapy. Recent evidence suggests a subtype of cells within HER2-positive breast tumors that concomitantly expresses the urokinase plasminogen activator receptor (uPAR) with inherent stem cell/mesenchymal-like properties promoting tumor cell motility and a metastatic phenotype. This HER-positive/uPAR-positive subtype may be partially responsible for the failure of HER2-targeted treatment strategies. Herein we discuss and substantiate the cumulative preclinical and clinical evidence on HER2-uPAR cooperativity in terms of gene co-amplification and/or... (More)
Human epidermal growth factor receptor type 2 (HER2)-positive breast carcinoma is highly aggressive and mostly metastatic in nature though curable/manageable in part by molecular targeted therapy. Recent evidence suggests a subtype of cells within HER2-positive breast tumors that concomitantly expresses the urokinase plasminogen activator receptor (uPAR) with inherent stem cell/mesenchymal-like properties promoting tumor cell motility and a metastatic phenotype. This HER-positive/uPAR-positive subtype may be partially responsible for the failure of HER2-targeted treatment strategies. Herein we discuss and substantiate the cumulative preclinical and clinical evidence on HER2-uPAR cooperativity in terms of gene co-amplification and/or mRNA/protein co-overexpression. We then propose a regulatory signaling model that we hypothesize to maintain upregulation and cooperativity between HER2 and uPAR in aggressive breast cancer. An improved understanding of the HER2/uPAR interaction in breast cancer will provide critical biomolecular information that may help better predict disease course and response to therapy. (Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Oncoscience
volume
2
issue
3
pages
207 - 224
publisher
Impact Journals
external identifiers
  • pmid:25897424
  • scopus:84947616846
ISSN
2331-4737
language
English
LU publication?
yes
id
b95c106f-2d5e-48c9-a515-d9465ba66897 (old id 5341095)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25897424?dopt=Abstract
date added to LUP
2016-04-04 09:45:33
date last changed
2022-03-23 07:08:13
@article{b95c106f-2d5e-48c9-a515-d9465ba66897,
  abstract     = {{Human epidermal growth factor receptor type 2 (HER2)-positive breast carcinoma is highly aggressive and mostly metastatic in nature though curable/manageable in part by molecular targeted therapy. Recent evidence suggests a subtype of cells within HER2-positive breast tumors that concomitantly expresses the urokinase plasminogen activator receptor (uPAR) with inherent stem cell/mesenchymal-like properties promoting tumor cell motility and a metastatic phenotype. This HER-positive/uPAR-positive subtype may be partially responsible for the failure of HER2-targeted treatment strategies. Herein we discuss and substantiate the cumulative preclinical and clinical evidence on HER2-uPAR cooperativity in terms of gene co-amplification and/or mRNA/protein co-overexpression. We then propose a regulatory signaling model that we hypothesize to maintain upregulation and cooperativity between HER2 and uPAR in aggressive breast cancer. An improved understanding of the HER2/uPAR interaction in breast cancer will provide critical biomolecular information that may help better predict disease course and response to therapy.}},
  author       = {{Indira Chandran, Vineesh and Eppenberger-Castori, Serenella and Venkatesh, Thejaswini and Vine, Kara Lea and Ranson, Marie}},
  issn         = {{2331-4737}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{207--224}},
  publisher    = {{Impact Journals}},
  series       = {{Oncoscience}},
  title        = {{HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer.}},
  url          = {{http://www.ncbi.nlm.nih.gov/pubmed/25897424?dopt=Abstract}},
  volume       = {{2}},
  year         = {{2015}},
}